Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 28361465)

  • 1. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.
    Beck A; Lambert J; Sun M; Lin K
    MAbs; 2012; 4(6):637-47. PubMed ID: 22909934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-generation antibody drug conjugates for cancer therapy--a balancing act.
    Vankemmelbeke M; Durrant L
    Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
    Cianfriglia M
    Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
    Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-conjugated antibodies for the treatment of cancer.
    Lambert JM
    Br J Clin Pharmacol; 2013 Aug; 76(2):248-62. PubMed ID: 23173552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Tarantino P; Tolaney SM
    Cancer Res; 2022 Oct; 82(20):3659-3661. PubMed ID: 36245247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.